

Cigna
Oncology Medication and Code List

*****Please note: This list constantly evolves as a result of new drugs coming to market (and being approved by the U.S. Food and Drug Administration) and the Centers for Medicare & Medicaid Services issuing Healthcare Common Procedure Coding System (HCPCS) code changes. Please contact EviCore healthcare, if the drug you are requesting is not contained on this list, to determine if prior authorization is needed*****

The integrated medical and pharmacy oncology management program supports both the customer and provider by incorporating a National Comprehensive Cancer Network® reviewed 'regimen of care' for the entire course of medication treatment.

- *Providers should submit prior authorization requests to Cigna for drugs that will be used for non-oncology indications.*
- *Oral medications are eligible for coverage under your Cigna patient's pharmacy benefit.*
- *Coverage for specialty injectables is determined by your patient's benefit plan. When benefits allow, certain injectables may be covered under your patient's pharmacy benefit.*
- *Under many benefit plans, medically necessary services must be rendered in the least intensive setting that is appropriate for the delivery of the services and supplies. Where applicable, your patient's benefit plan may compare the cost-effectiveness of alternative services, settings, or supplies when determining the least intensive setting.*
- *Certain specialty medical injectables must be dispensed and their claims must be submitted by a specialty pharmacy with which Cigna has a reimbursement arrangement, unless otherwise authorized by Cigna. When applicable, Cigna may grant an exception to reimburse a one-time, or single, administration billed by a facility when a customer needs access to the injectable before it can be obtained from a specialty pharmacy with which Cigna has a reimbursement arrangement.*

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | Cigna Commercial | Drug Comments |
|--------------------------------|---|---------|--------------------------|-------------------------|--------------------------|------------------|---------------|
| 5-Fluorouracil- Injection | 5FU, Adrucil | J9190 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Abemaciclib - oral | Verzenio | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Abiraterone Acetate - oral | Yonsa (not interchangeable with Zytiga) | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Abiraterone Acetate - oral | Zytiga (not interchangeable with Yonsa) | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Acalabrutinib - oral | Calquence | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Adagrasib - oral | Krazati | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Ado-Trastuzumab Emtansine | Kadcyla | J9354 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Afatinib - oral | Gilotrif | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Aldesleukin | Proleukin, Interleukin-2 | J9015 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Alectinib - oral | Alecensa | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| All-trans Retinoic Acid - oral | Vesanoid, ATRA, Tretinoin | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Alpelisib - oral | Piqray | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Amivantamab-vmjw | Rybrevant | J9061 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Apalutamide - oral | Erleada | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Aprepitant | Cinvanti | J0185 | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE | Y | |
| Aprepitant - oral | Emend | J8501 | Medical Oncology - SPORT | Supportive - Antiemetic | ORAL | Y | |
| Arsenic Trioxide | Trisenox | J9017 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Asciminib - oral | Scemblix | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | Cigna Commercial | Drug Comments |
|--|------------------|---------|--------------------------|----------------------|--------------------------|------------------|---|
| Asparaginase | Erwinaze | J9019 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Asparaginase erwinia chrysanthemi (recombinant)-rywn | Rylaze | J9021 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Atezolizumab | Tecentriq | J9022 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Avapritinib - oral | Ayvakit | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Avelumab | Bavencio | J9023 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Axitinib - oral | Inlyta | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Azacitidine | Vidaza | J9025 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Azacitidine - oral | Onureg | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | Medicare Part B |
| Belantamab Mafodotin-blmf | Blenrep | J9037 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Belinostat | Beleodaq | J9032 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Belzutifan - oral | Welireg | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Bendamustine HCL | Treanda | J9033 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bendamustine HCL | Bendeka | J9034 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bendamustine HCL | Belrapzo | J9036 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bendamustine HCL (apotex) | | J9058 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bendamustine HCL (baxter) | | J9059 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bendamustine HCL (vivimusta) | | J9056 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bevacizumab | Avastin | J9035 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bevacizumab (Radiation Necrosis) | Avastin | J9035 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | Supportive pathway for the use of Avastin to treat Radiation Induced Necrosis of the CNS |
| Bevacizumab-adcd | Vegzelma | Q5129 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | Supportive pathway for the use of Vegzelma to treat Radiation Induced Necrosis of the CNS |
| Bevacizumab-adcd | Vegzelma | Q5129 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bevacizumab-awwb | Mvasi | Q5107 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Bevacizumab-awwb (Radiation Necrosis) | Mvasi | Q5107 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | Supportive pathway for the use of Mvasi to treat Radiation Induced Necrosis of the CNS |
| Bevacizumab-bvzr | Zirabev | Q5118 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | Supportive pathway for the use of Zirabev to treat Radiation Induced Necrosis of the CNS |
| Bevacizumab-bvzr | Zirabev | Q5118 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Bevacizumab-maly | Alymsys | Q5126 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Bevacizumab-maly (Radiation Necrosis) | Alymsys | Q5126 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | Supportive pathway for the use of Alymsys to treat Radiation Induced Necrosis of the CNS |
| Bexarotene - oral | Targretin | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Bexarotene - topical | Targretin gel | C9399 | Medical Oncology - CHEMO | Primary | TOPICAL | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | Cigna Commercial | Drug Comments |
|-----------------------------|------------------|---------|--------------------------|------------|--------------------------|------------------|-----------------|
| Bexarotene - topical | Targetin gel | J3490 | Medical Oncology - CHEMO | Primary | TOPICAL | Y | |
| Binimetinib - oral | Mektovi | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Bleomycin | Blenoxane | J9040 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Blinatumomab | Blincyto | J9039 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bortezomib | Velcade | J9041 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bortezomib (fresenius kabi) | | J9048 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bortezomib (hospira) | | J9049 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bortezomib (maia) | | J9051 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Bosutinib - oral | Bosulif | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Brentuximab Vedotin | Adcetris | J9042 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Brigatinib - oral | Alunbrig | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Burosumab-twza | Crysvita | J0584 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Cabazitaxel | Jevtana | J9043 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Cabazitaxel (sandoz) | | J9064 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Cabozantinib - oral | Cabometyx | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Cabozantinib - oral | Cometriq | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Calaspargase pegol-mknl | Asparlas | J9118 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Capecitabine - oral | Xeloda (150 mg) | J8520 | Medical Oncology - CHEMO | Primary | ORAL | Y | Medicare Part B |
| Capecitabine - oral | Xeloda (500 mg) | J8521 | Medical Oncology - CHEMO | Primary | ORAL | Y | Medicare Part B |
| Capivasertib - oral | Truqap | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Capmatinib - oral | Tabrecta | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Carboplatin | Paraplatin | J9045 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Carfilzomib | Kyprolis | J9047 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Carmustine (accord) | | J9052 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Cemiplimab-rwlc | Libtayo | J9119 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Ceritinib - oral | Zykadia | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Cetuximab | Erbix | J9055 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Cisplatin | Platinol | J9060 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Cladribine | Leustatin | J9065 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Clofarabine | Clolar | J9027 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Cobimetinib - oral | Cotellic | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | Cigna Commercial | Drug Comments |
|------------------------------------|-----------------------|---------|--------------------------|-------------------------|--------------------------|------------------|---|
| Crizotinib - oral | Xalkori | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Cyclophosphamide - oral | Cytosan | J8530 | Medical Oncology - CHEMO | Primary | ORAL | Y | Medicare Part B |
| Cytarabine | Ara-C | J9100 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Cytarabine-Liposome | DepoCyt | J9098 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Dabrafenib - oral | Tafinlar | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Dacarbazine | DTIC-Dome | J9130 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Dacomitinib - oral | Vizimpro | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Dactinomycin | Cosmegen, Actinomycin | J9120 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Daratumumab | Darzalex | J9145 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Daratumumab and hyaluronidase-fihj | Darzalex Faspro | J9144 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Darbepoetin alfa | Aranesp | J0881 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Darolutamide - oral | Nubeqa | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Dasatinib - oral | Sprycel | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Daunorubicin | Cerubidine | J9150 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Decitabine | Dacogen | J0894 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Decitabine (sun pharma) | | J0893 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Decitabine and cedazuridine - oral | Inqovi | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Degarelix | Firmagon | J9155 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Denosumab | Xgeva, Prolia | J0897 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Denosumab | Xgeva, Prolia | J0897 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | Primary chemo pathway for the use of Xgeva to treat Giant Cell Tumor. |
| Denosumab-bbdz | Wyost, Jubbonti | C9399 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | New supportive biosimilar for Xgeva and Prolia effective: 03/19/24 |
| Denosumab-bbdz | Wyost, Jubbonti | J3490 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | New supportive biosimilar for Xgeva and Prolia effective: 03/19/24 |
| Denosumab-bbdz | Wyost, Jubbonti | J3590 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | New supportive biosimilar for Xgeva and Prolia effective: 03/19/24 |
| Denosumab-bbdz | Wyost, Jubbonti | J9999 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | New supportive biosimilar for Xgeva and Prolia effective: 03/19/24 |
| Dinutuximab | Unituxin | C9399 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Dinutuximab | Unituxin | J9999 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Docetaxel | Taxotere | J9171 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Docetaxel (ingenus) | | J9172 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Dolasetron Mesylate | Anzemet | J8597 | Medical Oncology - SPORT | Supportive - Antiemetic | ORAL | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | Cigna Commercial | Drug Comments |
|-----------------------------|--|---------|--------------------------|-------------------------|--------------------------|------------------|--|
| Dostarlimab-gxly | Jemperli | J9272 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Doxorubicin HCL | Adriamycin | J9000 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Doxorubicin HCL (liposomal) | Doxil, Doxorubicin HCL (Liposomal) not otherwise specified | Q2050 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Dronabinol - oral | Syndros, Marinol (Brand Only for Cigna) | Q0167 | Medical Oncology - SPORT | Supportive - Antiemetic | ORAL | Y | |
| Durvalumab | Imfinzi | J9173 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Duvelisib - oral | Copiktra | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Efbemalenograstim alfa-vuxw | Ryzneuta | C9399 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Efbemalenograstim alfa-vuxw | Ryzneuta | J3490 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Efbemalenograstim alfa-vuxw | Ryzneuta | J3590 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Efbemalenograstim alfa-vuxw | Ryzneuta | J9999 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Eflapegrastim-xnst | Rolvedon | J1449 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Eflornithine - oral | lwifin | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | New primary oral chemotherapy drug effective: 01/04/24 |
| Elacestrant - oral | Orserdu | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Elotuzumab | Empliciti | J9176 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Elranatamab-bcmm | Elrexio | J1323 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | New permanent HCPC Code: J1323 will replace NOC Code: C9165 & J9999 for Elrexio, effective: 04/01/24 |
| Elranatamab-bcmm | Elrexio | C9165 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Elranatamab-bcmm | Elrexio | J9999 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Enasidenib - oral | IDHIFA | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Encorafenib - oral | Braftovi | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Enfortumab vedotin-ejfv | Padcev | J9177 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Entrectinib - oral | Rozlytrek | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Enzalutamide - oral | Xtandi | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Epcoritamab-bysp | Epkinly | J9321 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Epirubicin | Elence | J9178 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Epoetin alfa | Epogen, Procrit | J0885 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Epoetin alfa-epbx | Retacrit | Q5106 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Erdafitinib-oral | Balversa | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Eribulin mesylate | Halaven | J9179 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Erlotinib - oral | Tarceva | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | Cigna Commercial | Drug Comments |
|------------------------------------|-----------------------------|---------|--------------------------|-------------------------|--------------------------|------------------|---|
| Etoposide - inj | Toposar, VePesid, Etopophos | J9181 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Everolimus - oral | Afinitor | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Fam-trastuzumab deruxtecan-nxki | Enhertu | J9358 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Fedratinib - oral | Inrebic | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Filgrastim | Neupogen | J1442 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Filgrastim-ayow | Releuko | Q5125 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Floxuridine | FUDR | J9200 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Fludarabine Phosphate | Fludara, Oforta | J9185 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Fosaprepitant | Emend | J1453 | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE | Y | |
| Fosaprepitant (focinvez) | | J1434 | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE | Y | New manufacturer code: J1434 for Fosaprepitant, effective: 04/01/24 |
| Fosaprepitant (teva) | | J1456 | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE | Y | |
| Fosnetupitant/Palonosetron | Akynzeo | J1454 | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE | Y | |
| Fruquintinib - oral | Fruzaqla | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Fulvestrant | Faslodex | J9395 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Fulvestrant (fresenius kabi) | | J9394 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Fulvestrant (teva) | | J9393 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Futibatinib - oral | Lytgobi | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Gefitinib - oral | Iressa | J8565 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Gemcitabine | Gemzar | J9201 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Gemcitabine HCL in NaCL | Infugem | J9198 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Gemcitabine Hydrochloride (accord) | | J9196 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Gemtuzumab Ozogamicin | Mylotarg | J9203 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Gilteritinib - oral | Xospata | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Glasdegib - oral | Daurismo | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Glofitamab-gxbm | Columvi | J9286 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Goserelin acetate implant | Zoladex | J9202 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Granisetron - subcutaneous | Sustol | J1627 | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE | Y | |
| Granisetron - transdermal | Sancuso | J3490 | Medical Oncology - SPORT | Supportive - Antiemetic | TRANSDERMAL | Y | |
| Histrelin Implant | Vantas | J9225 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Ibrutinib - oral | Imbruvica | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Idarubicin HCL - inj | Idamycin | J9211 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | Cigna Commercial | Drug Comments |
|--|---|---------|--------------------------|------------|--------------------------|------------------|---------------|
| Idelalisib - oral | Zydelig | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Ifosfamide | Ifex, Mitoxana | J9208 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Imatinib - oral | Gleevec | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Imatinib - oral | Gleevec | S0088 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Inotuzumab Ozogamicin | Besponsa | J9229 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Interferon, alfa-2b, recombinant | Intron A | J9214 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Interferon, gamma-1b | Actimmune | J9216 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Ipilimumab | Yervoy | J9228 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Irinotecan | Camptosar | J9206 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Irinotecan Liposome | Onivyde | J9205 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Isatuximab-irfc | Sarclisa | J9227 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Ivosidenib - oral | Tibsovo | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Ixabepilone | Ixempra | J9207 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Ixazomib - oral | Ninlaro | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Lanreotide | Somatuline Depot | J1930 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Lanreotide (cipla) | | J1932 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Lapatinib - oral | Tykerb | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Larotrectinib - oral | Vitrakvi | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Lenalidomide - oral | Revlimid | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Lenvatinib - oral | Lenvima | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Leuprolide Acetate (cipla) | | J1954 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Leuprolide Acetate (J1950: 3.75mg) | Eligard, Lupron Depot, Lupron, Leuprolide Acetate | J1950 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Leuprolide Acetate (J9217: 7.5mg) | Eligard, Lupron Depot, Lupron, Leuprolide Acetate | J9217 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Leuprolide Acetate (J9218: 1mg) | Lupron | J9218 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Leuprolide Mesylate | Camcevi | J1952 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Levoleucovorin | Fusilev | J0641 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Levoleucovorin | Khapzory | J0642 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Liposome-encapsulated combination of Daunorubicin and Cytarabine | Vyxeos | J9153 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Loncastuximab tesirine-tpyl | Zynlonta | J9359 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Lorlatinib - oral | Lorbrena | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Lurbinectedin | Zepzelca | J9223 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | Cigna Commercial | Drug Comments |
|--|------------------|---------|--------------------------|-------------------------|--------------------------|------------------|---|
| Luspatercept-aamt | Reblozyl | J0896 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Margetuximab-cmkb | Margenza | J9353 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Melphalan (apotex) | | J9249 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | New manufacture code: J9249 for Melphalan, effective: 04/01/24 |
| Melphalan (hepzato) | | J9248 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | New manufacture code: J9248 for Melphalan, effective: 04/01/24 |
| Melphalan HCL - inj | Evomela | J9246 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Melphalan HCL - NOS inj | Alkeran | J9245 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Midostaurin - oral | Rydapt | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Mirvetuximab Soravtansine-gynx | Elahere | J9063 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Mitomycin | Mutamycin | J9280 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Mitomycin | Jelmyto | J9281 | Medical Oncology - CHEMO | Primary | PYELOCALYCEAL | Y | Medicare Part B |
| Mitoxantrone HCL | Novantrone | J9293 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Mobocertinib - oral | Exkivity | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Mogamulizumab-kpkc | Poteligeo | J9204 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Momelotinib - oral | Ojjaara | J8499 | Medical Oncology - CHEMO | Primary | ORAL | Y | J8499 will replace C9399 & J9999 for Ojjaara, effective: 04/01/24 |
| Momelotinib - oral | Ojjaara | C9399 | Medical Oncology - CHEMO | Primary | ORAL | Y | J8499 will replace C9399 & J9999 for Ojjaara, effective: 04/01/24 |
| Momelotinib - oral | Ojjaara | J9999 | Medical Oncology - CHEMO | Primary | ORAL | Y | J8499 will replace C9399 & J9999 for Ojjaara, effective: 04/01/24 |
| Mosunetuzumab-axgb | Lunsumio | J9350 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Moxetumomab pasudotox-tdfk | Lumoxiti | J9313 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Naxitamab-gqgk | Danyelza | J9348 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Necitumumab | Portrazza | J9295 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Nelarabine | Arranon | J9261 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Neratinib - oral | Nerlynx | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Netupitant/Palonosetron - oral | Akynzeo | J8655 | Medical Oncology - SPORT | Supportive - Antiemetic | ORAL | Y | |
| Nilotinib - oral | Tasigna | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Nilutamide - oral | Nilandron | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Niraparib - oral | Zejula | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Niraparib and Abiraterone Acetate - Oral | Akeega | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Nirogacestat - oral | Ogsiveo | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Nivolumab | Opdivo | J9299 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | Cigna Commercial | Drug Comments |
|--|------------------|---------|--------------------------|-------------------------|--------------------------|------------------|---------------|
| Nivolumab and Relatimab-rmbw | Opdualag | J9298 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Obinutuzumab | Gazyva | J9301 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Octreotide depot | Sandostatin | J2353 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Octreotide depot | Sandostatin | J2353 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Octreotide non-depot | Sandostatin | J2354 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Octreotide non-depot | Sandostatin | J2354 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Ofatumumab | Arzerra | J9302 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Olaparib - oral | Lynparza | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Olutasidenib - oral | Rezlidhia | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Omacetaxine | Synribo | J9262 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Osimertinib - oral | Tagrisso | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Oxaliplatin | Eloxatin | J9263 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Paclitaxel | Nov-Onxol, Taxol | J9267 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Paclitaxel (albumin-bound) | Abraxane | J9264 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Paclitaxel albumin-bound (american regent) | | J9259 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Paclitaxel protein-bound (teva) | | J9258 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pacritinib - oral | Vonjo | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Palbociclib - oral | Ibrance | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Palonosetron | Aloxi | J2469 | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE | Y | |
| Panitumumab | Vectibix | J9303 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pazopanib - oral | Votrient | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Pegaspargase | Oncaspar | J9266 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pegfilgrastim, excludes biosimilar, 0.5 mg | Neulasta | J2506 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Pegfilgrastim-apgf | Nyvepria | Q5122 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Pegfilgrastim-bmez | Ziextenzo | Q5120 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Pegfilgrastim-cbqv | Udenyca | Q5111 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Pegfilgrastim-fpgk | Stimufend | Q5127 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Pegfilgrastim-jmdb | Fulphila | Q5108 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Pegfilgrastim-pbbk | Flyneta | Q5130 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Peginterferon, alfa-2a | Pegasys | S0145 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pembrolizumab | Keytruda | J9271 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | Cigna Commercial | Drug Comments |
|---|--|---------|--------------------------|----------------------|--------------------------|------------------|---------------|
| Pemetrexed | Pemfexy | J9304 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed | Alimta, Pemetrexed not otherwise specified | J9305 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed (accord) | | J9296 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed (bluepoint) | | J9322 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed (hospira) | | J9323 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed (novaplus / hospira) | | J9294 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed (pemrydi rtu) | | J9324 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed (sandoz) | | J9297 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemetrexed (teva) | | J9314 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pemigatinib - oral | Pemazyre | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Pentostatin | Nipent | J9268 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pertuzumab | Perjeta | J9306 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pertuzumab / trastuzumab / hyaluronidase-zzxf | Phesgo | J9316 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pexidartinib - oral | Turalio | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Pirtobrutinib - oral | Jaypirca | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Polatuzumab vedotin-piiq | Polivy | J9309 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pomalidomide - oral | Pomalyst | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Ponatinib - oral | Iclusig | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Pralatrexate | Folotyng | J9307 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Pralsetinib - oral | Gavreto | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Quizartinib - oral | Vanflyta | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Ramucirumab | Cyramza | J9308 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Regorafenib - oral | Stivarga | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Relugolix - oral | Orgovyx | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Reprotectinib - oral | Augtyro | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Relifanlimab-dlwr | Zynyz | J9345 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Ribociclib - oral | Kisqali | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Ripretinib - oral | Qinlock | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Rituximab | Rituxan | J9312 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Rituximab and Hyaluronidase Human | Rituxan Hycela | J9311 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Rituximab-abbs | Truxima | Q5115 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | Cigna Commercial | Drug Comments |
|---|------------------------|---------|--------------------------|-------------------------|--------------------------|------------------|---|
| Rituximab-arrx | Riabni | Q5123 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Rituximab-pvvr | Ruxience | Q5119 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Rolapitant - oral | Varubi | J8670 | Medical Oncology - SPORT | Supportive - Antiemetic | ORAL | Y | |
| Romidepsin (lyophilized) | Istodax | J9319 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Romidepsin (non-lyophilized) | | J9318 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Romiplostim | Nplate | J2796 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | Supportive drug used to treat myelosuppressive doses of radiation. |
| Ropeginterferon alfa-2b-njft | Besremi | C9399 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Ropeginterferon alfa-2b-njft | Besremi | J9999 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Rucaparib - oral | Rubraca | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Ruxolitinib - oral | Jakafi | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Sacituzumab govitecan-hziy | Trodelyv | J9317 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Selinexor - oral | Xpovio | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Selpercatinib - oral | Retevmo | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Selumetinib - oral | Koselugo | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Services provided as a part of a phase I clinical trial | Clinical Trial Phase 1 | S9988 | Medical Oncology - CHEMO | Primary | Varies per trial | Y | |
| Services provided as a part of a phase II clinical trial | Clinical Trial Phase 2 | S9990 | Medical Oncology - CHEMO | Primary | Varies per trial | Y | |
| Services provided as a part of a phase III clinical trial | Clinical Trial Phase 3 | S9991 | Medical Oncology - CHEMO | Primary | Varies per trial | Y | |
| Siltuximab | Sylvant | J2860 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Sipuleucel-T | Provenge | Q2043 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Sirolimus protein-bound particles for injectable suspension (albumin bound) | Fyarro | J9331 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Sodium Thiosulfate Injection | Pedmark | J0208 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Sodium Thiosulfate injection (hope) | | J0209 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | New manufacturer code: J0209 for Sodium Thiosulfate effective: 04/01/24 |
| Sonidegib - oral | Odomzo | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Sorafenib Tosylate - oral | Nexavar | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Sotorasib - oral | Lumakras | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Streptozocin | Zanosar | J9320 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Sunitinib - oral | Sutent | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Tafasitamab-cxix | Monjuvi | J9349 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Tagraxofusp-erzs | Elzonris | J9269 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Talazoparib - oral | Talzenna | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | Cigna Commercial | Drug Comments |
|--------------------------|------------------|---------|--------------------------|----------------------|--------------------------|------------------|--|
| Talimogene Laherparepvec | Imlygic | J9325 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Talquetamab-tgvs | Talvey | J3055 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | New permanent HCPC Code: J3055 will replace NOC Codes: C9163 & J9999 for Talvey, effective: 04/01/24 |
| Talquetamab-tgvs | Talvey | C9163 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Talquetamab-tgvs | Talvey | J9999 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | New permanent HCPC Code: J3055 will replace NOC Codes: C9163 & J9999 for Talvey, effective: 04/01/24 |
| Tazemetostat - oral | Tazverik | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Tbo-filgrastim | Granix | J1447 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Tebentafusp-tebn | Kimtrak | J9274 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Teclistamab-cqyv | Tecvayli | C9148 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Teclistamab-cqyv | Tecvayli | J9380 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Teclistamab-cqyv | Tecvayli | J9999 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Telotristat ethyl - oral | Xermelo | J8499 | Medical Oncology - SPORT | Supportive | ORAL | Y | |
| Temozolomide - inj | Temodar | J9328 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Temozolomide - oral | Temodar | J8700 | Medical Oncology - CHEMO | Primary | ORAL | Y | Medicare Part B |
| Temsirolimus | Torisel | J9330 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Teniposide | Vumon | Q2017 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Tepotinib - oral | Tepmetko | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Thalidomide - oral | Thalomid | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Thiotepa | Thioplex | J9340 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Tisotumab vedotin-tftv | Tivdak | J9273 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Tivozanib - oral | Fotivda | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Tocilizumab | Actemra | J3262 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | Supportive pathway for the use of Actemra for CAR-T induced CRS |
| Tocilizumab | Actemra | J3262 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Tocilizumab-bavi | Tofidence | Q5133 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | New Permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24 |
| Tocilizumab-bavi | Tofidence | Q5133 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | New permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24. Supportive biosimilar for the use of Actemra for CAR-T induced CRS. |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | Cigna Commercial | Drug Comments |
|------------------------------------|-------------------|---------|--------------------------|----------------------|--------------------------|------------------|--|
| Tocilizumab-bavi | Tofidence | C9399 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | New Permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24 |
| Tocilizumab-bavi | Tofidence | C9399 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | New permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24. Supportive biosimilar for the use of Actemra for CAR-T induced CRS. |
| Tocilizumab-bavi | Tofidence | J9999 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | New Permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24 |
| Tocilizumab-bavi | Tofidence | J9999 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | New permanent HCPC Code: Q5133 will replace NOC Codes: C9399 & J9999 for Tofidence, effective: 04/01/24. Supportive biosimilar for the use of Actemra for CAR-T induced CRS. |
| Topotecan - inj | Hycamtin | J9351 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Topotecan - oral | Hycamtin | J8705 | Medical Oncology - CHEMO | Primary | ORAL | Y | Medicare Part B |
| Toripalimab-tpzi | Loqtorzi | C9399 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Toripalimab-tpzi | Loqtorzi | J9999 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Trabectedin | Yondelis | J9352 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Trametinib - oral | Mekinist | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Trametinib - powder for suspension | Mekinist | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Trastuzumab | Herceptin | J9355 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Trastuzumab and hyaluronidase-oysk | Herceptin Hylecta | J9356 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Trastuzumab-anns | Kanjinti | Q5117 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Trastuzumab-dkst | Ogivri | Q5114 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Trastuzumab-dttb | Ontruzant | Q5112 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Trastuzumab-pkrb | Herzuma | Q5113 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Trastuzumab-qyyp | Trazimera | Q5116 | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE | Y | |
| Tremelimumab-actl | Imjudo | J9347 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Trifluridine/Tipiracil - oral | Lonsurf | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Trilaciclib | Cosela | J1448 | Medical Oncology - SPORT | Supportive | INJECTABLE | Y | |
| Triptorelin Pamoate | Treistar | J3315 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Tucatinib - oral | Tukysa | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Vandetanib - oral | Caprelsa | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |

Effective Date: 04/01/2024

| Description | Alt Descriptions | Primary | Program | Drug Class | Administration Technique | Cigna Commercial | Drug Comments |
|----------------------|-----------------------|---------|--------------------------|------------|--------------------------|------------------|---------------|
| Vemurafenib - oral | Zelboraf | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Venetoclax - oral | Venclexta | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Vinblastine Sulfate | Velban | J9360 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Vincristine Sulfate | Oncovin, Vincasar PFS | J9370 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Vinorelbine Tartrate | Navelbine | J9390 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |
| Vismodegib - oral | Erivedge | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Vorinostat - oral | Zolinza | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Zanubrutinib - oral | Brukinsa | J8999 | Medical Oncology - CHEMO | Primary | ORAL | Y | |
| Ziv-Aflibercept | Zaltrap | J9400 | Medical Oncology - CHEMO | Primary | INJECTABLE | Y | |